Carfilzomib-60mg/vial (CARFILNAT)
Carfilzomib 60mg/Vial Injection (CARFILNAT) is an oncology medicine containing carfilzomib, a proteasome inhibitor used in the management of multiple myeloma. It works by targeting specific cancer cell processes to help control disease progression. This injection is supplied as a single-dose vial and is administered under the supervision of qualified healthcare professionals. Carfilzomib 60mg/Vial Injection is designed for use as part of a prescribed treatment regimen based on the patient’s medical condition. Always follow the recommended dosage, storage instructions, and administration guidelines provided by the healthcare specialist.
Description
Carfilzomib 60mg/Vial Injection (CARFILNAT) is an advanced oncology medicine that contains carfilzomib as its active ingredient. This medication belongs to the class of proteasome inhibitors and plays an important role in the treatment approach for multiple myeloma.
Carfilzomib works by blocking the activity of proteasomes, which are protein-processing systems inside cells. By interfering with this process, the medicine helps create an environment that affects the survival and multiplication of cancer cells. Doctors may recommend this therapy alone or in combination with other medicines depending on the patient’s health condition, treatment response, and medical history.
Carfilzomib 60mg/Vial Injection comes in a single-dose vial formulation and requires administration through intravenous infusion by trained healthcare professionals. The healthcare provider determines the appropriate dosage schedule according to individual treatment requirements. Patients should follow all medical instructions regarding dosage, infusion duration, and monitoring during therapy.
This oncology injection requires proper handling and storage conditions to maintain its quality and effectiveness. Healthcare facilities should store and prepare the product according to the manufacturer’s guidelines. Medical professionals monitor patients during treatment to evaluate therapeutic response and manage any possible reactions.
Carfilzomib 60mg/Vial Injection provides a targeted treatment option for patients requiring proteasome inhibitor therapy in multiple myeloma management. Its specialized mechanism of action supports modern oncology care by focusing on specific pathways involved in cancer cell function.
Before starting treatment, patients should discuss their complete medical history, current medications, and existing health conditions with their doctor. Only qualified healthcare professionals should prescribe and administer this medicine to ensure safe and effective use.
CARFILNAT 60mg Injection represents a clinically used option in oncology treatment protocols and should always be used under strict medical supervision for optimal patient care.
- Product Name: Carfilzomib 60mg/Vial (CARFILNAT)
- Generic Name: Carfilzomib
- Strength: 60mg per vial
- Dosage Form: Injection
- Therapeutic Category: Antineoplastic / Oncology Medicine
- Drug Class: Proteasome Inhibitor
- Primary Use: Management of Multiple Myeloma
- Administration: Intravenous infusion under medical supervision
- Packaging: Single-dose vial
- Active Ingredient: Carfilzomib
- Storage: Store as directed on the product label and by healthcare professionals
